1. Home
  2. GNLX vs RVPHW Comparison

GNLX vs RVPHW Comparison

Compare GNLX & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNLX
  • RVPHW
  • Stock Information
  • Founded
  • GNLX 2001
  • RVPHW N/A
  • Country
  • GNLX United States
  • RVPHW United States
  • Employees
  • GNLX N/A
  • RVPHW 15
  • Industry
  • GNLX Biotechnology: Pharmaceutical Preparations
  • RVPHW Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNLX Health Care
  • RVPHW Health Care
  • Exchange
  • GNLX Nasdaq
  • RVPHW Nasdaq
  • Market Cap
  • GNLX N/A
  • RVPHW N/A
  • IPO Year
  • GNLX 2023
  • RVPHW 2018
  • Fundamental
  • Price
  • GNLX $2.33
  • RVPHW $0.14
  • Analyst Decision
  • GNLX Strong Buy
  • RVPHW
  • Analyst Count
  • GNLX 3
  • RVPHW 0
  • Target Price
  • GNLX $22.33
  • RVPHW N/A
  • AVG Volume (30 Days)
  • GNLX 153.3K
  • RVPHW N/A
  • Earning Date
  • GNLX 11-12-2024
  • RVPHW N/A
  • Dividend Yield
  • GNLX N/A
  • RVPHW N/A
  • EPS Growth
  • GNLX N/A
  • RVPHW N/A
  • EPS
  • GNLX N/A
  • RVPHW N/A
  • Revenue
  • GNLX $8,000.00
  • RVPHW N/A
  • Revenue This Year
  • GNLX N/A
  • RVPHW N/A
  • Revenue Next Year
  • GNLX N/A
  • RVPHW N/A
  • P/E Ratio
  • GNLX N/A
  • RVPHW N/A
  • Revenue Growth
  • GNLX N/A
  • RVPHW N/A
  • 52 Week Low
  • GNLX $1.60
  • RVPHW N/A
  • 52 Week High
  • GNLX $26.07
  • RVPHW N/A
  • Technical
  • Relative Strength Index (RSI)
  • GNLX 51.46
  • RVPHW N/A
  • Support Level
  • GNLX $1.95
  • RVPHW N/A
  • Resistance Level
  • GNLX $2.43
  • RVPHW N/A
  • Average True Range (ATR)
  • GNLX 0.17
  • RVPHW 0.00
  • MACD
  • GNLX -0.01
  • RVPHW 0.00
  • Stochastic Oscillator
  • GNLX 56.21
  • RVPHW 0.00

About RVPHW Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: